0.4865
Talphera Inc stock is traded at $0.4865, with a volume of 9,544.
It is down -3.79% in the last 24 hours and down -14.00% over the past month.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
See More
Previous Close:
$0.4781
Open:
$0.49
24h Volume:
9,544
Relative Volume:
0.23
Market Cap:
$9.43M
Revenue:
$2.82M
Net Income/Loss:
$-14.20M
P/E Ratio:
-0.5724
EPS:
-0.85
Net Cash Flow:
$-15.13M
1W Performance:
-8.31%
1M Performance:
-14.00%
6M Performance:
-40.26%
1Y Performance:
-55.34%
Talphera Inc Stock (TLPH) Company Profile
Compare TLPH with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
TLPH
Talphera Inc
|
0.46 | 10.29M | 2.82M | -14.20M | -15.13M | -0.85 |
![]()
HLN
Haleon Plc Adr
|
11.13 | 50.54B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
ZTS
Zoetis Inc
|
170.84 | 74.02B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
RDHL
Redhill Biopharma Ltd Adr
|
1.8368 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.95 | 45.82B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.22 | 20.31B | 16.54B | -1.64B | 749.00M | -1.45 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
Jul-20-20 | Downgrade | Credit Suisse | Neutral → Underperform |
Nov-11-19 | Downgrade | Credit Suisse | Outperform → Neutral |
Aug-05-19 | Resumed | Credit Suisse | Outperform |
Jul-10-19 | Resumed | Credit Suisse | Outperform |
Apr-24-19 | Resumed | B. Riley FBR | Buy |
Feb-15-19 | Initiated | Credit Suisse | Outperform |
Oct-23-18 | Initiated | B. Riley FBR | Buy |
Oct-13-17 | Downgrade | Jefferies | Buy → Hold |
Oct-13-17 | Reiterated | RBC Capital Mkts | Outperform |
Jul-14-17 | Resumed | Jefferies | Buy |
Sep-15-16 | Reiterated | ROTH Capital | Buy |
Aug-05-16 | Downgrade | Stifel | Buy → Hold |
Oct-30-15 | Upgrade | Jefferies | Hold → Buy |
Oct-05-15 | Reiterated | ROTH Capital | Buy |
Sep-02-15 | Initiated | H.C. Wainwright | Buy |
Jul-10-15 | Resumed | ROTH Capital | Buy |
May-06-15 | Reiterated | Mizuho | Neutral |
May-05-15 | Reiterated | RBC Capital Mkts | Outperform |
Mar-10-15 | Reiterated | RBC Capital Mkts | Outperform |
Mar-09-15 | Downgrade | Mizuho | Buy → Neutral |
View All
Talphera Inc Stock (TLPH) Latest News
Financial Review: Talphera (NASDAQ:TLPH) & Alterity Therapeutics (NASDAQ:ATHE) - Defense World
Talphera, Inc. (NASDAQ:TLPH) Q1 2025 Earnings Call Transcript - MSN
Talphera’s Strategic Advancements and Financial Stability Reinforce Buy Rating - TipRanks
Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing - MSN
Talphera, Inc. Earnings Call: Strategic Adjustments and Financial Progress - TipRanks
TLPH Prepares to Finalize NEPHRO CRRT Registration Trial | TLPH Stock News - GuruFocus
Talphera: Q1 Earnings Snapshot - Greenwich Time
Talphera Inc (TLPH) Q1 2025 Earnings Call Highlights: Strategic Cost Reductions and FDA ... - Yahoo Finance
Talphera, Inc. Reports Q1 2025 Financial Results - TipRanks
Talphera Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Talphera Inc. outlines strategic shifts in Q1 2025 - Investing.com Nigeria
TLPH Reports Strong Q1 Revenue with Promising Study Progress | T - GuruFocus
Talphera Inc Reports Q1 2025 EPS Loss of $0.10, Beating Estimates; Revenue Details Unavailable - GuruFocus
TALPHERA, INC. SEC 10-Q Report - TradingView
TLPH Reports Strong Q1 Revenue with Promising Study Progress | TLPH Stock News - GuruFocus
Talphera Announces First Quarter 2025 Financial Results and Prov - GuruFocus
Talphera Cuts Net Loss 32%, Secures FDA Approval for Streamlined Clinical Trial Design - Stock Titan
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update | TLPH Stock News - GuruFocus
Talphera reports Q1 EPS (10c), consensus (14c) - TipRanks
Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 - Citizen Tribune
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 14, 2025 | TLPH Stock News - GuruFocus
All You Need to Know About Talphera (TLPH) Rating Upgrade to Strong Buy - Yahoo Finance
HC Wainwright Predicts Talphera’s Q1 Earnings (NASDAQ:TLPH) - Defense World
Talphera (TLPH) Upgraded to Buy: What Does It Mean for the Stock? - MSN
HC Wainwright Estimates Talphera FY2029 Earnings - Defense World
Talphera CEO Makes Bold Move with Major Stock Purchase! - TipRanks
Talphera CEO Vincent Angotti buys $124,999 in common stock By Investing.com - Investing.com Canada
Talphera CEO Vincent Angotti buys $124,999 in common stock - Investing.com
Talphera (NASDAQ:TLPH) Given Buy Rating at HC Wainwright - Defense World
Talphera, Inc. Earnings Call: Progress Amid Challenges - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target By Investing.com - Investing.com Canada
Strategic Advancements and FDA Agreement Propel Talphera’s Positive Outlook with Buy Rating - TipRanks
H.C. Wainwright maintains Buy on Talphera stock, $6 target - Investing.com India
Talphera: Q4 Earnings Snapshot - CT Insider
Talphera Inc (TLPH) Q4 2024 Earnings Call Highlights: Strategic Moves and Financial Insights - Yahoo Finance
Talphera Reports 2024 Financial Results and Study Update - TipRanks
Talphera outlines 2025 timeline for NEPHRO CRRT study completion and FDA approval of Niyad - MSN
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus - Investing.com India
FDA approves Talphera’s reduced NEPHRO CRRT study size By Investing.com - Investing.com South Africa
Earnings call transcript: Talphera Inc Q4 2024 shows strategic focus By Investing.com - Investing.com UK
TLPH stock touches 52-week low at $0.5 amid market challenges By Investing.com - Investing.com South Africa
TALPHERA, INC. SEC 10-K Report - TradingView
Talphera Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Talphera Inc Stock (TLPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Talphera Inc Stock (TLPH) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Aslam Shakil | Chief Medical Officer |
Jun 14 '24 |
Buy |
1.07 |
5,000 |
5,357 |
37,695 |
Aslam Shakil | Chief Medical Officer |
Jun 13 '24 |
Buy |
0.98 |
695 |
681 |
32,695 |
Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Dec 05 '24 |
Buy |
0.64 |
5,000 |
3,200 |
208,066 |
ASADORIAN RAFFI | Chief Financial Officer |
Dec 02 '24 |
Sale |
0.77 |
155 |
119 |
37,578 |
Angotti Vincent J. | CHIEF EXECUTIVE OFFICER |
Nov 27 '24 |
Buy |
0.73 |
5,000 |
3,650 |
203,066 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):